Oncologist Mikhail Blagosklonny Continuous Support of Rapamycin to Improve Immunity in Aging Humans
Oncologist and Researcher, Dr. Mikhail Blagosklonny is passionate about his works in the field of oncology to find cures for cancer and living disease-free. After years of studying internal medicine, experimental medicine, and cardiology at First Pavlov State Medical University of St. Petersburg, he joined New York Medical College as Associate Professor of Medicine. In his prior career, he also served as Professor of Oncology at Roswell Park Cancer Institute, and Senior Scientist for Ordway Research Institute. His research is focused on anti-aging, biogerontology, cancer, and treatment therapies that prevent damages to healthy cells. Dr. Blagosklonny published an article regarding the anti-aging drug Rapamycin and it’s possible side effects in humans, on Impact Journals, in 2015. Visit classroomvoices.org to read more about Mikhail.
Mikhail Blagosklonny is co-editor of Oncotarget and is author of 300 research articles, reviews, and chapters in various books. His research article published, in 2015, on rejuvenating immunity anti-aging drug, Rapamycin made national headlines. Dr. Blagosklonny said that Everolimus, a rapamycin analog showed signs of immunity improvement in aging adults. It was described as a turning point in research, in 2014, which was predicted 15 years ago. When the article was published, he said aging was perceived as a declining function because of accumulation of damaged random molecules.
After years of studying rapamycin anti-aging drug, Blagosklonny says the hyper-function theory describes aging as a continuous growth. TOR, also known as Target of Rapamycin is said to be one of the signaling pathways behind its driving force. Rapamycin and other rapalogs are predicted to be used in humans to treat aging and prevent diseases, based on the TOR-centric model. Mikhail said when doses are administered properly and on schedule, the anti-aging drug prolongs healthy life expectancy.
Mikhail Blagosklonny is a faithful advocate for Rapamycin, which was approved for clinical testing, in 2006, to treat cancer, Alzheimer’s, osteoporosis, and other diseases. He supports the anti-aging drug and created a hypothesis for TOR and its role in treating cancer and anti-aging. His thorough understanding of oncology had led him to be one of the most recognizable researchers in the world. Classroom Voices said Mikhail recommends the drug as a possible treatment to extend life. Data collected from clinical and preclinical testing of the drug is promising as cancer treatment that has some side effects.
Mikhail Blagosklonny is presently the Professor of Oncology and Scientist studying cancer and aging. He has written research papers and articles about chemotherapy engineering, the aging hyper-function theory, and cell cyclotherapy. Since TOR was discovered by Michael Hall, nearly 12 years ago, the model is proven to provide possible results for treating specific diseases and cancers. Blagosklonny believes in Rapamycin and says with calorie restriction it can delay diseases related to aging.